These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32241872)

  • 21. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
    Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
    Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation.
    Yuwen H; Wang H; Li T; Ren Y; Zhang YK; Chen P; Sun A; Bian G; Li B; Flowers D; Presler M; Subramanian K; Xue J; Wang J; Lynch K; Mei J; He X; Shan B; Hou B
    Cancer Res; 2024 May; 84(10):1680-1698. PubMed ID: 38501978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The anti-lymphoma activities of anti-CD137 monoclonal antibodies are enhanced in FcγRIII(-/-) mice.
    Sallin MA; Zhang X; So EC; Burch E; Cai L; Lin W; Chapoval AI; Strome SE
    Cancer Immunol Immunother; 2014 Sep; 63(9):947-58. PubMed ID: 24927849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
    Milone MC; Fish JD; Carpenito C; Carroll RG; Binder GK; Teachey D; Samanta M; Lakhal M; Gloss B; Danet-Desnoyers G; Campana D; Riley JL; Grupp SA; June CH
    Mol Ther; 2009 Aug; 17(8):1453-64. PubMed ID: 19384291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
    Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
    J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism.
    Eguren-Santamaría I; Rodríguez I; Herrero-Martin C; Fernández de Piérola E; Azpilikueta A; Sánchez-Gregorio S; Bolaños E; Gomis G; Molero-Glez P; Chacón E; Mínguez JÁ; Chiva S; Diez-Caballero F; de Andrea C; Teijeira Á; Sanmamed MF; Melero I
    Oncoimmunology; 2024; 13(1):2373519. PubMed ID: 38988823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
    Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
    Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
    Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
    J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
    Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
    J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis.
    Etxeberria I; Glez-Vaz J; Teijeira Á; Melero I
    ESMO Open; 2020 Jul; 4(Suppl 3):e000733. PubMed ID: 32611557
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
    Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity.
    Cheng LS; Cheng YF; Liu WT; Shen A; Zhang D; Xu T; Yin W; Cheng M; Ma X; Wang F; Zhao Q; Zeng X; Zhang Y; Shen G
    J Transl Med; 2022 Sep; 20(1):415. PubMed ID: 36076251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8
    Aznar MA; Labiano S; Diaz-Lagares A; Molina C; Garasa S; Azpilikueta A; Etxeberria I; Sanchez-Paulete AR; Korman AJ; Esteller M; Sandoval J; Melero I
    Cancer Immunol Res; 2018 Jan; 6(1):69-78. PubMed ID: 29133290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.
    Campbell JR; McDonald BR; Mesko PB; Siemers NO; Singh PB; Selby M; Sproul TW; Korman AJ; Vlach LM; Houser J; Sambanthamoorthy S; Lu K; Hatcher SV; Lohre J; Jain R; Lan RY
    Cancer Res; 2021 Jun; 81(11):2983-2994. PubMed ID: 33757978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
    Huang PL; Kan HT; Hsu CH; Hsieh HT; Cheng WC; Huang RY; You JJ
    J Transl Med; 2023 May; 21(1):346. PubMed ID: 37226226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
    Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.
    Stagg J; Loi S; Divisekera U; Ngiow SF; Duret H; Yagita H; Teng MW; Smyth MJ
    Proc Natl Acad Sci U S A; 2011 Apr; 108(17):7142-7. PubMed ID: 21482773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BT7480, a novel fully synthetic
    Hurov K; Lahdenranta J; Upadhyaya P; Haines E; Cohen H; Repash E; Kanakia D; Ma J; Kristensson J; You F; Campbell C; Witty D; Kelly M; Blakemore S; Jeffrey P; McDonnell K; Brandish P; Keen N
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.